1. Home
  2. NTCT vs PHVS Comparison

NTCT vs PHVS Comparison

Compare NTCT & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NetScout Systems Inc.

NTCT

NetScout Systems Inc.

HOLD

Current Price

$27.68

Market Cap

2.0B

Sector

Technology

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$28.32

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTCT
PHVS
Founded
1984
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.7B
IPO Year
1999
2021

Fundamental Metrics

Financial Performance
Metric
NTCT
PHVS
Price
$27.68
$28.32
Analyst Decision
Buy
Buy
Analyst Count
2
9
Target Price
$31.00
$39.44
AVG Volume (30 Days)
405.7K
205.6K
Earning Date
02-05-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.24
N/A
Revenue
$862,770,000.00
N/A
Revenue This Year
$5.90
N/A
Revenue Next Year
$2.62
N/A
P/E Ratio
$22.47
N/A
Revenue Growth
9.60
N/A
52 Week Low
$18.12
$11.51
52 Week High
$30.67
$29.80

Technical Indicators

Market Signals
Indicator
NTCT
PHVS
Relative Strength Index (RSI) 53.34 61.89
Support Level $26.70 $24.51
Resistance Level $28.29 $26.68
Average True Range (ATR) 0.78 1.58
MACD 0.01 0.20
Stochastic Oscillator 62.96 92.73

Price Performance

Historical Comparison
NTCT
PHVS

About NTCT NetScout Systems Inc.

NetScout Systems Inc is a provider of service assurance and cybersecurity solutions to enterprise and government networks. It bases its solutions on proprietary adaptive service intelligence technology, which helps customers monitor and identify performance issues and provides insight into network-based security threats. These solutions also deliver real-time and historical information, which provides insight to restore service and understand the quality of user experience. The company derives revenue from the sale of network management tools and security solutions. Its geographical regions include USA, which derives maximum revenue, Europe, Asia, and Rest of the World.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: